|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Identification of a novel coronavirus causing severe pneumonia in human:a descriptive study显示文摘Background:Human infections with zoonotic coronaviruses(CoVs),including severe acute respiratory syndrome(SARS)-CoV and Middle East respiratory syndrome(MERS)-CoV,have raised great public health concern globally.Here,we report a novel batorigin CoV causing severe and fatal pneumonia in humans.Methods:We collected clinical data and bronchoalveolar lavage(BAL)specimens from five patients with severe pneumonia from Wuhan Jinyintan Hospital,Hubei province,China.Nucleic acids of the BAL were extracted and subjected to next-generation sequencing.Virus isolation was carried out,and maximum-likelihood phylogenetic trees were constructed.Results:Five patients hospitalized from December 18 to December 29,2019 presented with fever,cough,and dyspnea accompanied by complications of acute respiratory distress syndrome.Chest radiography revealed diffuse opacities and consolidation.One of these patients died.Sequence results revealed the presence of a previously unknownβ-CoV strain in all five patients,with 99.8%to 99.9%nucleotide identities among the isolates.These isolates showed 79.0%nucleotide identity with the sequence of SARS-CoV(GenBank NC_004718)and 51.8%identity with the sequence of MERS-CoV(GenBank NC_019843).The virus is phylogenetically closest to a bat SARS-like CoV(SL-ZC45,GenBank MG772933)with 87.6%to 87.7%nucleotide identity,but is in a separate clade.Moreover,these viruses have a single intact open reading frame gene 8,as a further indicator of bat-origin CoVs.However,the amino acid sequence of the tentative receptor-binding domain resembles that of SARS-CoV,indicating that these viruses might use the same receptor.Conclusion:A novel bat-borne CoV was identified that is associated with severe and fatal respiratory disease in humans. | Li-Li Ren Ye-Ming Wang Zhi-Qiang Wu Zi-Chun Xiang Li Guo Teng Xu Yong-Zhong Jiang Yan Xiong Yong-Jun Li Xing-Wang Li Hui Li Guo-Hui Fan Xiao-Ying Gu Yan Xiao Hong Gao Jiu-Yang Xu Fan Yang Xin-Ming Wang Chao Wu Lan Chen Yi-Wei Liu Bo Liu Jian Yang Xiao-Rui Wang Jie Dong Li Li Chao-Lin Huang Jian-Ping Zhao Yi Hu Zhen-Shun Cheng Un-Lin Liu Zhao-Hui Qian Chuan Qin Qi Jin Bin Cao Jian-Wei Wang | 2020 | Chinese Medical Journal2020，，9： | 99 |
| 2 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 3 | A complete sequence and comparative analysis of a SARS-associated virus(Isolate BJ01)显示文摘The genome sequence of the Severe Acute Respiratory Syndrome (SARS)-associated virus provides essential information for the identification of pathogen(s), exploration of etiology and evolution, interpretation of transmission and pathogenesis, development of diagnostics, prevention by future vaccination, and treatment by developing new drugs. We report the complete genome sequence and comparative analysis of an isolate (BJ01) of the coronavirus that has been recognized as a pathogen for SARS. The genome is 29725 nt in size and has 11 ORFs (Open Reading Frames). It is composed of a stable region encoding an RNA-dependent RNA polymerase (composed of 2 ORFs) and a variable region representing 4 CDSs (coding sequences) for viral structural genes (the S, E, M, N proteins) and 5 PUPs (putative uncharacterized proteins). Its gene order is identical to that of other known coronaviruses. The sequence alignment with all known RNA viruses places this virus as a member in the family of Coronaviridae. Thirty putative substitutions have been identified by comparative analysis of the 5 SARS- associated virus genome sequences in GenBank. Fifteen of them lead to possible amino acid changes (non-synonymous mutations) in the proteins. Three amino acid changes, with predicted alteration of physical and chemical features, have been detected in the S protein that is postulated to beinvolved in the immunoreactions between the virus and its host. Two amino acid changes have been detected in the Mprotein, which could be related to viral envelope formation. Phylogenetic analysis suggests the possibility of non-human origin of the SARS-associated viruses but provides noevidence that they are man-made. Further efforts should focus on identifying the etiology of the SARS-associated virus and ruling out conclusively the existence of otherpossible SARS-related pathogen(s). | QIN E'de ZHU Qingyu YU Man FAN Baochang CHANG Guohui SI Bingyin YANG Bao PENG Wenming JIANG Tao LIU Bohua DENG Yongqiang LIU Hong ZHANG Yu WANG Cui LI Yuquan GAN Yonghua LI Xiaoyu L Fushuang TAN Gang CAO Wuchun, YANG Ruifu Institute of Microbiology and Epidemiology, Chinese Academy of Military Medical Sciences, Beijing 100071, China WANG Jian, LI Wei, XU Zuyuan, LI Yan, WU Qingfa, LIN Wei, CHEN Weijun, TANG Lin, DENG Yajun, HAN Yujun, LI Changfeng, LEI Meng, LI Guoqing, LI Wenjie, L Hong, SHI Jianping, TONG Zongzhong, ZHANG Feng, LI Songgang, LIU Bin, LIU Siqi, DONG Wei, WANG Jun, Gane K-S Wong, YU Jun & YANG Huanming* Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300 National Center for Genome Information, Beijing 101300, China | 2003 | Chinese Science Bulletin2003，48，10： | 121 |
| 4 | Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein显示文摘AIM To compare the therapeutic effect andsignificances of multimodality treatment forhepatocellular carcinoma (HCC) with tumorthrombi in portal vein (PVTT).METHODS HCC patients (n = 147) with tumortrombi in the main portal vein or the first branchof portal vein were divided into four groups bythe several therapeutic methods. There wereconservative treatment group in 18 out ofpatients (group A); and hepatic artery ligation(HAL) and/or hepatic artery infusion (HAl)group in 18 patients (group B), in whompostoberative chemoembolization was doneperiodically; group of removal of HCC with PVTTin 79 (group C) and group of transcatheterhepatic arterial chemoembolization (TACE) orHAl and/or portal vein infusion (PVI) afteroperation in 32 (group D).RESULTS The median survival period was 12months in our series and the 1-, 3-, and 5-yearsurvival rates were 44.3%, 24.5% and 15.2%,respectively. The median survival times were 2,5, 12 and 16 months in group A, B, C and D,respectively. The 1-, 3- and 5-year survival rateswere 5.6%, 0% and 0% in group A; 22.2%,5.6% and 0% in group B; 53.9%, 26.9% and16.6% in group C; 79.3%, 38.9% and 26.8% ingroup D, respectively. Significant differenceappeared in the survival rates among the groups(P<0.05).CONCLUSION Hepatic resection with removalof tumor thrombi and HCC should increase thecurative effects and be encouraged for theprolongation of life span and quality of life forHCC patients with PVTT, whereas the besttherapeutic method for HCC with PVTT is withregional hepatic chemotherapy orchemoemblization after hepatic resection withremoval of tumor thrombi. | Jia Fan Zhi Quan Wu Zhao You Tang Jian Zhou Shuang Jian Qiu Zeng Chen Ma Xin Da Zhou Sheng Long Ye Liver Cancer Institute, Zhongshan Hospital, Fudan University Medical Center (Former Shanghai University), 136 Yixueyuan Road, Shanghai 200032, China | 2001 | World Journal of Gastroenterology2001，7，1： | 80 |
| 5 | Comparative Study between Robotic Total Thyroidectomy with Central Lymph Node Dissection via Bilateral Axillo-breast Approach and Conventional Open Procedure for Papillary Thyroid Microcarcinoma显示文摘 | Qing-Qing He Jian Zhu Da-Yong Zhuang Zi-Yi Fan Lu-Ming Zheng Peng Zhou Lei Hou Fang Yu Yan-Ning Li Lei Xiao Xue-Feng Dong Gao-Feng Ni | 2016 | Chinese Medical Journal2016，，18： | 42 |
| 6 | Dihydroartemisinin is an inhibitor of ovarian cancer cell growth显示文摘瞄准:调查 dihydroartemisinin (DHA ) 的反癌症活动,在人的卵巢的癌症房间的一块面板的反疟疾药 artemisinin 的衍生物排队。方法: 房间生长被 MTT 生存能力试金决定。Apoptosis 和房间周期前进被 DNA 破碎胶化电气泳动,流动 cytometry 试金,和 TUNEL 试金评估;蛋白质和 mRNA 表示被西方的弄污和 RT-PCR 试金分析。结果:Artemisininand 它的衍生物包括 artesunate, arteether, artemether, arteannuin,和 DHA,在人的卵巢的癌症细胞的 exhibitanticancer 生长活动。在他们之中, DHA 在禁止房间生长是最有效的。卵巢的癌症房间线是更敏感的(5-10-fold ) 到与正常相比的 DHA 治疗,卵巢的房间排队。在微臼齿的剂量层次的 DHA 展出剂量 -- 在卵巢的癌症房间的 andtime 依赖的 cytotoxicity 排队。而且, DHA 导致了 apoptosis 和 G2cell 周期拘捕,由 Bcl-xL 和 Bcl-2 和 Bax 和 Bad.Conclusion 的增加的减少伴随了:有希望的结果第一次证明 DHA 禁止人的卵巢的癌症房间的生长。房间生长, apoptosis 正式就职,和 G2 拘捕在卵巢的癌症的临床的治疗作为可能的反癌症药为 DHA 的进一步的研究在 vitro 证据提供的卵巢的癌症的选择抑制。 | Yang JIAO Chun-min GE Qing-hui MENG Jian-ping CAO Jian TONG Sai-jun FAN | 2007 | Acta Pharmacologica Sinica2007，28，7： | 39 |
| 7 | Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice显示文摘最近的研究开始在心脏的肥大和机能障碍的致病揭示了 microRNAs (miRNAs ) 的关键角色。在这研究,我们测试了是否转变生长 factor-β(TGF-β) 调整 miRNA 在心脏的肥大和心失败(HF ) 的发展起了一个枢轴的作用。我们观察到 miR-27b 是在 cardiomyocyte 特定的 Smad4 猛烈老鼠的心的 upregulated,它开发了心脏的肥大。在 vitro,实验证明 miR-27b 表示能被 TGF-β 禁止; 1 并且它的 overexpression 支持了 hypertrophic 房间生长,当 miR-27b 抑制导致了 hypertrophic 房间的抑制时,生长由 phenylephrine (PE ) 引起了处理。而且,有 miR-27b 的 cardiomyocyte 特定的 overexpression 的转基因的老鼠的分析表明 miR-27b overexpression 是足够的导致心脏的肥大和机能障碍。我们验证了 peroxisome 激活 proliferator 的 receptor-γ(PPAR-γ) 作为在 cardiomyocyte 的 miR-27b 的一个直接目标。一致地, miR-27b 转基因的老鼠显著地显示了 PPAR-γ 的底层;比控制鼠标。而且,在用在一只 pressure-overload-induced 老鼠的特定的 antagomir 的 miR-27b 的 vivo silencing, HF 的模型增加了心脏的 PPAR-γ表示,稀释心脏的肥大和机能障碍。我们的学习的结果表明那 TGF-β 1-regulated miR-27b 涉及心脏的肥大的规定,并且为心脏病作为一个有效治疗学的目标验证 miR-27b。 | Jian Wang Yao Song Yan Zhang Han Xiao Qiang Sun Ning Hou Shuilong Guo Youliang Wang Kaiji Fan Dawei Zhan Lagabaiyila Zha Yang Cao Zhenhua Li Xuan Cheng Youyi Zhang Xiao Yang | 2012 | Cell Research2012，22，3： | 36 |
| 8 | Buyang Huanwu decoction increases angiopoietin-1 expression and promotes angiogenesis and functional outcome after focal cerebral ischemia显示文摘 | Jian SHEN Yu ZHU Hai YU Zuo-xu FAN Feng XIAO Pan WU Qi-hui ZHANG Xiao-xing XIONG Jian-wei PAN Ren-ya ZHAN | 2014 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2014，15，3： | 36 |
| 9 | Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis显示文摘Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. | Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng | 2019 | Neural Regeneration Research2019，14，3： | 35 |
| 10 | Volumetric-modulated arc therapy vs c-IMRT in esophageal cancer:A treatment planning comparison显示文摘AIM:To compare the volumetric-modulated arc therapy AT plans ith conventional sliding indo intensity-modulated radiotherapy c-I RT plans in esophageal cancer EC . METHODS:Tenty patients ith EC ere selected, including 5 cases located in the cervical, the upper, the middle and the lo er thorax, respectively. Five plans ere generated ith the eclipse planning system:three using c-IMRT with 5 fields (5F), 7 fields (7F) and 9 fields (9F), and two using VMAT with a single arc 1A and double arcs 2A . The treatment plans ere designed to deliver a dose of 60 Gy to the plan-ning target volume Tith the same constrains in a 2.0 Gy daily fraction, 5 d a eek. lans ere normalized to 95% of the T that received 100% of the prescribed dose. We examined the dose-volume histogram parameters of T and the organs at risk OAR such as lungs, spinal cord and heart. onitor units U and normal tissue complication probability NTC of OAR ere also reported. RESULTS:Both c-I RT and AT plans resulted in abundant dose coverage of T for EC of different locations. The dose conformity to T as improved as the number of field in c-IMRT or rotating arc in VMAT as increased. The doses to T and OAR in AT plans ere not statistically different in comparison ith c-I RT plans, ith the follo ing exceptions:in cervical and upper thoracic EC, the conformity index CI as higher in VMAT (1A 0.78 and 2A 0.8) than in c-IMRT (5F 0.62, 7F 0.66 and 9F 0.73) and homogeneity was slightly better in c-IMRT (7F 1.09 and 9F 1.07) than in VMAT (1A 1.1 and 2A 1.09). Lung V30 was lower in VMAT (1A 12.52 and 2A 12.29) than in c-IMRT (7F 14.35 and 9F 14.81). The humeral head doses were significantly increased in AT as against c-I RT. In the middle and lower thoracic EC, CI in VMAT (1A 0.76 and 2A 0.74) was higher than in c-IMRT (5F 0.63 Gy and 7F 0.67 Gy), and homogeneity was almost similar bet een AT and c-I RT. 20 2A 21.49 Gy vs 7F 24.59 Gy and 9F 24.16 Gy) and V30 (2A 9.73 Gy vs 5F 12.61 Gy, 7F 11.5 Gy and 9F 11.37 Gy) of lungs in AT ere lo er than in c-I RT, but lo doses to lungs (V5 and V10) were increased. V30 (1A 48.12 Gy vs 5F 59.2 Gy, 7F 58.59 Gy and 9F 57.2 Gy), V40 and 50 of heart in AT as lo er than in c-I RT. Us in AT plans ere significantly reduced in comparison ith c-I RT, maximum doses to the spinal cord and mean doses of lungs ere similar bet een the t o techniques. NTC of spinal cord as 0 for all cases. NTC of lungs and heart in AT ere lo er than inc-I RT. The advantage of AT plan as enhanced by doubling the arc. CONCLUSION:Compared ith c-I RT, AT, especially the 2A, slightly improves the OAR dose sparing, such as lungs and heart, and reduces NTC and U ith a better T coverage. | Li Yin Hao Wu Jian Gong Jian-Hao Geng Fan Jiang An-Hui Shi Rong Yu Yong-Heng Li Shu-Kui Han Bo Xu Guang-Ying Zhu | 2012 | World Journal of Gastroenterology2012，18，37： | 34 |
| 11 | Sorafenib in treatment of patients with advanced hepatocellular carcinoma:a systematic review显示文摘BACKGROUND: Sorafenib has become the standard first-line treatment for patients with advanced hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of sorafenib in advanced HCC patients and explore its true value for specific subgroups. DATA SOURCES: A computer-based systematic search from January 2005 to June 2011 with 'sorafenib' and 'advanced hepatocellular carcinoma' as search terms was performed for possible clinical trials. Hazard ratios (HR) and their 95% confidence intervals (CI) for overall survival (OS) and time to progression (TTP), rates of partial response (PR), rates of toxicity effects, and details of subgroup analysis were extracted. Meta-analyses were done using the software Review Manager (version 5.0). RESULTS: Six trials with 1164 patients were included. Based on three randomized controlled trials, the pooled HR (sorafenib/ placebo) was 0.66 for OS (95% CI: 0.56-0.78; P<0.00001) and 0.57 for TTP (95% CI: 0.47-0.68; P<0.00001). The pooled odds ratio (OR) for PR was 2.96 (95% CI: 0.96-9.15; P=0.06). For three single-arm trials, the pooled HR was 0.69 for OS (95% CI: 0.56-0.84; P=0.0002) and 0.64 for TTP (95% CI: 0.52-0.78; P<0.00001). The pooled OR for PR in three single-arm trials was 3.56 (95% CI: 1.22-10.39; P=0.02). Subgroup analysis indicated that sorafenib was less effective in patients with extrahepatic spread (with: P=0.13 vs without: P<0.0001), with normal alpha-fetoprotein level (AFP) (P=0.15 vs elevated: P=0.0006), and with elevated level of serum bilirubin (P=0.06 vs normal: P=0.0009). Sorafenib-based therapy significantly increased the risk of grade 3/4 hand-foot skin reaction, diarrhea, fatigue, and rash/desquamation.CONCLUSIONS: Sorafenib-based therapy benefits advanced HCC patients. Meanwhile, sorafenib is less effective for patients with extrahepatic spread, with normal AFP level and with elevated level of bilirubin. | Xin Zhang, Xin-Rong Yang, Xiao-Wu Huang, Wei-Min Wang, Ruo-Yu Shi, Yang Xu, Zheng Wang, Shuang-Jian Qiu, Jia Fan ,Jian Zhou Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai Key Laboratory for Organ Transplantation, Shanghai 200032, China,Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，5： | 29 |
| 12 | Role of cyclooxygenase-2 in gastric cancer development and progression显示文摘Although the incidence of gastric cancer has been declining in recent decades,it remains a major public health issue as the second leading cause of cancer death worldwide.In China,gastric cancer is still the main cause of death in patients with malignant tumors.Most patients are diagnosed at an advanced stage and mortality is high.Cyclooxygenase-2(COX-2)is a ratelimiting enzyme in prostanoid synthesis and plays an important role in the development and progression of gastric cancer.The expression of COX-2 in gastric cancer is upregulated and its molecular mechanisms have been investigated.Helicobacter pylori infection,tumor suppressor gene mutation and the activation of nuclear factor-kappa B may be responsible for the elevated expression of COX-2 in gastric cancer.The mechanisms of COX-2 in the development and progression of gastric cancer are probably through promoting the proliferation of gastric cancer cells,while inhibiting apoptosis,assisting angiogenesis and lymphatic metastasis,and participating in cancer invasion and immunosuppression.This review is intended to discuss,comment and summarize recent research progress on the role of COX-2 in gastric cancer development and progression,and elucidate the molecular mechanisms which might be involved in the carcinogenesis. | Jian Cheng Xiao-Ming Fan | 2013 | World Journal of Gastroenterology2013，19，42： | 29 |
| 13 | Minimal invasive microscopic tooth preparation in esthetic restoration: a specialist consensus显示文摘By removing a part of the structure,the tooth preparation provides restorative space,bonding surface,and finish line for various restorations on abutment.Preparation technique plays critical role in achieving the optimal result of tooth preparation.With successful application of microscope in endodontics for>30 years,there is a full expectation of microscopic dentistry.However,as relatively little progress has been made in the application of microscopic dentistry in prosthodontics,the following assumptions have been proposed:Is it suitable to choose the tooth preparation technique under the naked eye in the microscopic vision?Is there a more accurate preparation technology intended for the microscope?To obtain long-term stable therapeutic effects,is it much easier to achieve maximum tooth preservation and retinal protection and maintain periodontal tissue and oral function health under microscopic vision?Whether the microscopic prosthodontics is a gimmick or a breakthrough in obtaining an ideal tooth preparation should be resolved in microscopic tooth preparation.This article attempts to illustrate the concept,core elements,and indications of microscopic minimally invasive tooth preparation,physiological basis of dental pulp,periodontium and functions involved in tool preparation,position ergonomics and visual basis for dentists,comparison of tooth preparation by naked eyes and a microscope,and comparison of different designs of microscopic minimally invasive tooth preparation techniques.Furthermore,a clinical protocol for microscopic minimally invasive tooth preparation based on target restorative space guide plate has been put forward and new insights on the quantity and shape of microscopic minimally invasive tooth preparation has been provided. | Haiyang Yu Yuwei Zhao Junying Li Tian Luo Jing Gao Hongchen Liu Weicai Liu Feng Liu Ke Zhao Fei Liu Chufan Ma Juergen MSetz Shanshan Liang Lin Fan Shanshan Gao Zhuoli Zhu Jiefei Shen Jian Wang Zhimin Zhu Xuedong Zhou | 2019 | International Journal of Oral Science2019，11，4： | 25 |
| 14 | Gegen Qinlian decoction enhances immunity and protects intestinal barrier function in colorectal cancer patients via gut microbiota显示文摘BACKGROUND We previously showed,using the Traditional Chinese Medicine System Pharmacology Database,that Gegen Qinlian decoction(GQD)had a direct antitumor effect,and was combined with programmed cell death protein(PD)-1 inhibitors to treat microsatellite stable(MSS)tumor-bearing mice.However,the effect of GQD on patients with colorectal cancer(CRC)is not clear.AIM To determine the therapeutic mechanism of GQD in improving immune function,reducing inflammation and protecting intestinal barrier function.METHODS Seventy patients with CRC were included in this study:37 in the control group and 33 in the treatment group.The proportions of CD4+T,CD8+T,natural killer(NK),NKT and T regulatory cells were measured by flow cytometry.Levels of the cytokines tumor necrosis factor(TNF)-α,interferon(IFN)-γ,interleukin(IL)-2,IL-6,IL-10 and serotonin(5-hydroxytryptamine;5-HT)in serum were assessed by enzyme-linked immunosorbent assay(ELISA).The expression of zonula occludens(ZO)-1,occludin,nuclear factor(NF)-κB and TNF-αin tumor and normal tissues was measured by immunohistochemistry.The composition of gut microbiota from patients in the treatment group was assessed using 16S rDNA analysis.RESULTS There were no adverse events in the treatment group.The proportion of CD4+T cells and NKT cells in the post-treatment group was significantly higher than that in the pre-treatment and control groups(P<0.05).The level of TNF-αin the posttreatment group was significantly lower than that in the pre-treatment and control groups(P<0.05).The concentration of 5-HT in the post-treatment group was significantly lower than that in the pre-treatment group(P<0.05).The expression of ZO-1 and occludin in tumor tissues in the treatment group was significantly higher than that in the control group(P<0.05).The expression of ZO-1 in normal tissues of the treatment group was significantly higher than that in the control group(P=0.010).Compared with the control group,expression of NF-κB and TNF-αin tumor tissues of the treatment group was significantly decreased(P<0.05).Compared with the pre-treatment group,GQD decreased the relative abundance of Megamonas and Veillonella.In addition,GQD increased the relative abundance of Bacteroides,Akkermansia and Prevotella.CONCLUSION GQD enhances immunity and protects intestinal barrier function in patients with CRC by regulating the composition of gut microbiota. | Yang Li Zhong-Xin Li Chen-Yang Xie Jing Fan Ji Lv Xin-Jian Xu Jian Lv Wen-Tao Kuai Yi-Tao Jia | 2020 | World Journal of Gastroenterology2020，26，48： | 23 |
| 15 | Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing显示文摘Hepatocellular 癌(HCC ) 是癌症实质词法,基因并且 phenotypic 差异。然而,我们不理解在 intratumor 异质和肿瘤的联系词法 / 组织学的特征之间的关系。用介绍 96 个肿瘤房间(30-36 各个) 和 15 个正常的肝房间(5 各个) 的单个房间的整个染色体的定序,与联系 HBV 的 HCC 从三个男病人收集了,我们证实拷贝数字变化在 hepatocarcinogenesis 早发生,但是此后在整个肿瘤仍然保持相对稳定前进。重要地,我们证明特定的 HCC 能具有 monoclonal 或 polyclonal 起源。有汇合的 multinodular 形态学的肿瘤是典型 polyclonal 肿瘤并且显示最高的 intratumor 异质。除了 mutational 和拷贝数字侧面,我们把了用导出 HBV 的外国 genomic 标记的 HCC 的同种细胞的起源。在 monoclonal HCC,所有肿瘤单身者房间展出一样的 HBV 集成,显示 HBV 集成是一个早司机事件并且在肿瘤前进期间仍然保持极其稳定。另外,我们的结果显示那两个都转移,迟了的传播并且早播种当模特儿,在 HCC 有一个角色前进。尤其是,开始的克隆传播的早 intrahepatic 导致同步 multifocal 肿瘤的形成。同时,我们在 HCC 识别了潜在的司机基因 ZNF717,它展出变化的高频率在单个房间并且人口铺平,,通过调整 IL-6/STAT3 小径行动的肿瘤 suppressor。这些调查结果热点多重不同肿瘤在 HCC 的进化机制,它为特定的处理策略建议需要。 | Meng Duan, Shu Zhang, Zhichao Wang, Jieyi Shi, Longzi Liu, Xiaoying Wang, Aiwu Ke, Jian Zhou, Jia Fan, Qiang Gao Junfeng Hao, Chong Li Sijia Cui Daniel L Worthley Ya Cao Ruibin Xi Xiaoming Zhang Jian Zhou, Jia Fan Qiang Gao | 2018 | Cell Research2018，28，3： | 21 |
| 16 | Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy显示文摘Locoregional therapies(LRTs)of hepatocellular carcinoma(HCC)represented by ablation and TACE has become the main means for the clinical treatment of unresectable HCC.Among these,TACE is used throughout the stageⅠb toⅢb of HCC treatment.In recent years,immunotherapy led by immune checkpoint inhibitors has become a hot direction in clinical research.At the same time,targeted drugs such as Sorafenib and Apatinib have played an important role in the treatment and complementary therapy of advanced HCC,and their clinical application has been quite mature.HCC is the sixth most common malignant tumor in the world.When it comes to its treatment,different therapies have different indications,and their individual efficacies are not satisfactory,which makes the exploration of the use of combination therapy in HCC treatment become a new trend.In this paper,the status of the three therapies and the progress of their combined application are briefly reviewed. | Jian Xue Hongbo Ni Fan Wang Ke Xu Meng Niu | 2021 | Journal of Interventional Medicine2021，4，3： | 21 |
| 17 | Analogic China map constructed by DNA显示文摘In this research,a nanoscale DNA structure of analogic China map is created. The nanostructure of roughly 150 nm in diameter with a spatial resolution of 6 nm is purely constructed by folding DNA. The picture observed by atomic force microscopy (AFM) is almost identical with the de-signed shape. The DNA origami technology invented by Rothemund in 2006 is employed in the construc-tion of this shape,which has proved the capability of constructing almost any complicated shape enabled by DNA origami,and provides new bottom-up method for constructing nanostructures. | QIAN Lulu WANG Ying ZHANG Zhao ZHAO Jian PAN Dun ZHANG Yi LIU Qiang FAN Chunhai HU Jun HE Lin | 2006 | Chinese Science Bulletin2006，51，24： | 20 |
| 18 | Prevalence of and risk factors for postprandial hypotension in older Chinese men显示文摘ObjectiveTo 估计流行并且冒险因素因为在旧、很旧的中国 men.MethodsThe 学习之中的饭后的低血压(PPH ) 65 包括了 349 个中国人并且更旧,组织了进二个年龄范畴:组 1 (旧) 65 ~ 80 年包括了 163 个人;组 2 (很旧) 超过 80 年包括了 186 个人。在饭以后的血压变化被估计由监视的回廊血压的每 15 min。在饭摄取以后并且在相对血压变化处于基线条件站起来和变化以后的症状连续地被观察。另外的基线数据包括了身体团索引,病历,和 PPH 的药 use.ResultsThe 流行总的来说是 59.3% 并且比组织 1 在组 2 是显著地更高的(63.4% 对 54.6% , P <0.05 ) 。在组 2,在早餐(33.8%) 和午餐(32.1%) 以后的 PPH 的流行在晚饭(20.9%) 以后比那高, P <0.05。高血压和年龄是为 PPH 的重要风险因素(或 = 2.188, 95% CI:1.134 − 4.223, P = 0.02;或 = 1.86, 95% CI:1.112 − 3.11, P = 0.018,分别地) 。相反, acarbose 使用对 PPH 是保护的(或 = 0.4, 95% CI:0.189 − 0.847, P = 0.017 ) 。在血压的减少在 PPH 期间是 20 − 40 mmHg 和最大值是 90 mmHg。 PPH 通常发生在 30 − ;在饭以后的 60 min 并且持续了 30 − ; 120 min.ConclusionsThese 调查结果证明在超过 80 年的人的 PPH 的流行比在 65~80 年的人的那些显著地高,并且血压衰落为超过 80 年的人也是更高的。另外,高血压和年龄是为在老人的 PPH 的主要风险因素,它建议那阻止并且对待的 PPH 是值得的。 | Xiao ZOU Jian CAO Jian-Hua LI Yi-Xin HU Yu-Song GUO Quan-Jin SI Li FAN | 2015 | Journal of Geriatric Cardiology2015，12，6： | 20 |
| 19 | Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients显示文摘Dear Editor,Hepatocellular carcinoma(HCC)is the second most deadly cancer worldwide.1 Cirrhosis of different causes predisposes patients to HCC,increasing the annual HCC incidence by 2%–4%.1 The development of cirrhosis facilitates a series of genetic or epigenetic changes,resulting in the formation of dysplastic nodules,a premalignant stage in HCC.1 HCC diagnosis at an early stage contributes to an improved prognosis with the possibility of curative treatment.Due to the low accuracy of current diagnostic methods,it is urgently needed to explore new non-invasive strategies for early HCC diagnosis in cirrhotic patients. | Lei Chen Ghassan K.Abou-Alfa Bo Zheng Jing-Feng Liu Jian Bai Lu-Tao Du Yun-Song Qian Rong Fan Xiao-Long Liu Lin Wu Jin-Lin Hou Hong-Yang Wang The PreCar Team | 2021 | Cell Research2021，31，5： | 20 |
| 20 | Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma:Report of an initial experience显示文摘瞄准:报导收到了 sirolimus 的 36 个病人的初步的结果的回顾的分析(SRL, Rapamune, rapamycin ) 在 248 肝的一个连续的队紧密相联的接枝接受者。方法:被换到的有肝细胞癌(HCC ) 的 36 个肝 transplant 病人从 tacrolimus 的基于 SRL 的免疫力的抑制治疗在这研究被注册。是在常位的肝移植( OLT )前推进了 HCC 被诊断的病人被划分成组 A ( n = 11 ),在 OLT 被分配组织 B 以后,被发现到的那些有 HCC 复发或转移( n = 18 ),并且 calcineurin 禁止者( CNI )引起的发达肾机能不全被分到谁的那些组织 C ( n = 7 )在 OLT 以后。结果:病人被跟随在上面为一 10.4 瞬间中部(范围, 3.8-19.1 瞬间) 在到 SRL 治疗和 12.3 瞬间的变换以后(范围, 5.1-34.4 瞬间) 在 OLT 以后。开发的三个病人在开始 SRL 治疗以后的 2 wk,它是充分在氢化尼松以后颠倒了的温和尖锐细胞的拒绝搏动治疗。在组 A,仅仅 1 个病人被发现有 HCC 复发和转移在 OLT 以后的 12 瞬间。在组 B, 66.7%(12/18 ) 病人们(2 与进步肿瘤, 7 与稳定的肿瘤并且 3 没有肿瘤) 由于在 6.8 瞬间柱子变换和 10.7 瞬间柱子 transplant 的中部的后续的结束为 HCC 复发交谈到 SRL 或切除术仍然是活着的。在组 C,没有 HCC 复发在 7 个病人被表明,并且肾的功能在 SRL 治疗以后变得正常。血小板减少(n = 2 ) ,贫血症(n = 8 ) ,并且口头的 aphthous (n = 7 ) 在我们的队发现是容易可管理的。结论:到基于 SRL 的免疫力的抑制的变换可以禁止 HCC 的复发和转移并且与 HCC 在 OLT 病人改进导致 CNI 的肾机能不全。 | Jian Zhou Jia Fan Zheng Wang Zhi-Quan Wu Shuang-Jian Qiu Xiao-Wu Huang Yao Yu Jian Sun Yong-Sheng Xiao Yi-Feng He Yu-Qi Wang Zhao-You Tang | 2006 | World Journal of Gastroenterology2006，12，19： | 20 |
您所在的机构暂未开通此部分的功能，请联系管理员